The biotech sector is one of the first growth oriented groups that turned up and has been relatively strong all year. Likes this one because it has a diversified revenue line. Growing cash flow.
One of the largest bio-tech firms in the world.
He thinks there is not enough control, in knowing how research is going to be able to proceed. (phase 1 through phase 6).
Instead he uses PBE-A which is a portfolio. Less exciting but more rewarding long term.
Once a takeover bid comes in, it no longer trades on fundamentals. If you already own, keep the stock and wait to see what happens. You could take a bit of profit here.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.